EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis

Jose M Calderin iD, Sean Wasserman iD, Rosleine Antilus-Sainte, Melissa Cristaldo, Narineh M Odjourian, Faye Lanni, Firat Kaya, Noha Abdelgawad iD, Juan Eduardo Resendiz-Galvan iD, Matthew Zimmerman iD, Veronique Dartois iD, Paolo Denti iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00261-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Jose M Calderin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Meningeal, Central Nervous System. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Wellcome Discovery Research Platform in Infection, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment optimization through pharmacokinetic evaluation is needed to improve outcomes in tuberculous meningitis (TBM). Clinical assessment of drug penetration into the central nervous system (CNS) is limited to cerebrospinal fluid (CSF) sampling, which may not reflect drug exposures at the site-of-disease. We characterized the pharmacokinetics of antituberculosis drugs in CNS tissues using a rabbit model of TBM. Rabbits infected with Mycobacterium tuberculosis received human-equivalent doses of antituberculosis drugs after displaying signs of TBM. Blood was intensively sampled on day 1 and until euthanasia on day 3 when terminal plasma, CSF, and CNS tissues were collected. Total drug concentrations were quantified by LC–MS/MS and analyzed in NONMEM to estimate equilibration half-lives and CSF- and CNS tissue-to-plasma ratios. Across 5 experiments, 48 rabbits provided 600 plasma samples and 48 sets of terminal CSF/CNS tissue samples. Pyrazinamide and isoniazid showed high and consistent penetration, with CSF ratios of 0.98 and 0.85 and CNS tissue ratios ranging from 0.44 to 0.73 and 0.60–0.82, respectively. Linezolid demonstrated modest and uniform penetration (CSF ratio 0.39; CNS tissue ratios 0.15–0.44). Rifampicin showed the lowest overall penetration (CSF ratio 0.08; CNS tissue ratios 0.07–0.32). In contrast, the most lipophilic drugs, bedaquiline and rifabutin, showed low CSF ratios (0.01 and 0.42, respectively) compared with much higher CNS tissue ratios (1.11–6.34 and 1.23–6.78, respectively). CSF penetration in the rabbit TBM model closely mirrored reported human data, establishing its translational value. High relative CNS exposures of bedaquiline and rifabutin support their clinical evaluation for TBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, MeningealCentral Nervous SystemAnimalsRabbitsIsoniazidPyrazinamideMycobacterium tuberculosisDisease Models, AnimalRifampinLinezolidDiarylquinolinesFemaleTandem Mass SpectrometryRifabutinChromatography, Liquid

Stichwörter der Autor:innen

bedaquilinecentral nervous systemcerebrospinal fluidisoniazidlinezolidnonlinear mixed-effects modelingpharmacokineticspyrazinamiderabbit modelrifabutinrifampicintuberculous meningitis

Substanzen

Antitubercular AgentsIsoniazidPyrazinamideRifampinLinezolidDiarylquinolinesRifabutinbedaquiline

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
  • Wellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Afric…
  • Blizard Institute, Queen Mary University of London, London, United Kingdom.
  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States.
  • Hackensack Meridian School of Medicine, Nutley, New Jersey, United States.

ORCID-Profile: Jose M Calderin, Sean Wasserman, Noha Abdelgawad, Juan Eduardo Resendiz-Galvan, Matthew Zimmerman, Veronique Dartois, Paolo Denti, Martin Gengenbacher

Förderung

  • NIH HHS
  • Wellcome Discovery Research Platform in Infection
  • Bill and Melinda Gates Foundation
  • NIAID NIH HHS
  • Wellcome Trust
  • National Institutes of Health

Zitieren

APA

Calderin, J. M., Wasserman, S., Antilus-Sainte, R., Cristaldo, M., Odjourian, N. M., Lanni, F., Kaya, F., Abdelgawad, N., Resendiz-Galvan, J. E., Zimmerman, M., Dartois, V., Denti, P., & Gengenbacher, M. (2026). Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00261-26

Vancouver

Calderin JM, Wasserman S, Antilus-Sainte R, Cristaldo M, Odjourian NM, Lanni F, et al. Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00261-26

BibTeX
@article{Calderin2026,
  author = {Calderin, Jose M and Wasserman, Sean and Antilus-Sainte, Rosleine and Cristaldo, Melissa and Odjourian, Narineh M and Lanni, Faye and Kaya, Firat and Abdelgawad, Noha and Resendiz-Galvan, Juan Eduardo and Zimmerman, Matthew and Dartois, Veronique and Denti, Paolo and Gengenbacher, Martin},
  title = {Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00261-26}
}
Kostenlos starten →